The Biotechnology Innovation Organization (BIO) applauds the introduction of the “Advancing Emergency Preparedness Through One Health Act of 2018” by Senators Tina Smith (D-MN) and Todd Young (R-IN).

The Biotechnology Innovation Organization (BIO) today released the following statement in response to the introduction of the “Growing American Food Exports Act of 2018” by Representatives Neal Dunn (FL-02) and Jimmy Panetta (CA-20).

BIO today welcomed USDA’s release of a new report, Indicators of the U.S. Biobased Economy, which measures substantial economic growth, job creation, and household income from biofuel and bioenergy production and future growth in renewable chemicals and biobased products.

Washington, D.C. (March 20, 2018) – The following statement on the House introduction of the STRONGER Patents Act by Representatives Steve Stivers (R-OH-15) and Bill Foster (D-IL- 11) may be attributed to Tom DiLenge, BIO’s President, Advocacy, Law & Public Policy Division:“BIO supports balanced reforms to reduce abusive patent practices – both by patent owners and against patent owners.  But we also must strengthen the incentives needed to sustain our nation’s global leadership in biotechnology innovation and the creation of high-wage, high-value jobs throughout our country. With the introduction of the STRONGER Patents Act, Congress has begun the process of achieving that critical balance.“I commend Representatives Stivers and Foster for their leadership in introducing legislation that will reform the inter partes review and post-grant review processes, bringing fairness and finality to these Patent Office proceedings. The bill also will enhance patent quality by ensuring that all fees paid to the Patent Office are used for their intended purposes, and will crack down on abusive patent demand letters.“Strong patents are the lifeblood of the biotechnology industry. They are critical in ensuring a steady stream of capital to biotechnology companies developing innovative medicines and more sustainable sources of energy and agricultural products. And they are essential to the technology transfer process that leads from inventions in the lab to products on the shelves.“The majority of biotechnology companies are small companies that have no products on the market, and thus their research and development activities are funded through massive amounts of private sector investment over many years, sometimes even decades. Without strong, predictable and enforceable protections for patented inventions, investors will shy away from investing in biotechinnovation, degrading the ability to provide solutions to the most pressing medical,…

Washington, D.C. (March 16, 2018) – The Biotechnology Innovation Organization (BIO) commends Governor Matt Mead for signing critical legislation to create a pathway for the substitution of interchangeable biologic medicines, with appropriate communication to patients and physicians.Governor Mead signed Senate File 75 this week, following broad bipartisan support in both the Wyoming Senate and House. The policies outlined in the bill align with BIO’s principles on biologic substitution and garnered our support. BIO is grateful to Senator Fred Baldwin for his sponsorship of the bill, and to the legislature and Governor Mead for their leadership on this issue.“Senate File 75 enjoys the support of physicians across Wyoming and the country, patient groups, and both innovator biologic and biosimilar manufacturing companies. This bill includes provisions to ensure appropriate communication on all biologic medicines dispensed, in order to maintain a consistent and complete medical record,” said Jim Greenwood, BIO’s President and Chief Executive Officer. "By signing this bill into law, Governor Mead has added Wyoming to the list of states that allow retail pharmacies to substitute interchangeable biologic medicines."While the U.S. Food and Drug Administration (FDA) oversees approval of biologic medicines and designation of interchangeability, policies governing whether one product may be substituted in place of a doctor's prescription and whether a pharmacist must inform patients and doctors are covered by state law. Senate File 75 seeks to properly preserve patient access to accurate prescription information, maintain incentives for innovation and promote a competitive market for biologic therapies. BIO supports full communication in the substitution process, as patients and their physicians should know what biologic medicine the patient receives from the pharmacy.While the FDA has approved biosimilar products for sale in the U.S., the…

BIO submitted written testimony to the U.S. House Ways and Means Subcommittee on Tax Policy, for the hearing “Post Tax Reform Evaluation of Recently Expired Tax Provisions,” asking the committee to provide a seamless multi-year extension of the Second Generation Biofuel Producer Tax Credit; the Special Depreciation Allowance for Second Generation Biofuel Plant Property; the Biodiesel and Renewable Diesel Fuels Credit; and the Alternative Fuel Vehicle Refueling Property, which Congress recently extended retroactively for 2017 but are currently expired.

BIO regrets signing of misleading drug pricing and reporting bill by Oregon Governor Brown, as it will fail to provide patients the lower drug costs they were promised